- Home
- CXE vs LPTX Comparison
CXE vs LPTX Comparison
Compare CXE & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXE
- LPTX
- Stock Information
- Founded
- CXE 1989
- LPTX 2011
- Country
- CXE United States
- LPTX United States
- Employees
- CXE N/A
- LPTX N/A
- Industry
- CXE Investment Managers
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CXE Finance
- LPTX Health Care
- Exchange
- CXE Nasdaq
- LPTX Nasdaq
- Market Cap
- CXE N/A
- LPTX 119.6M
- IPO Year
- CXE N/A
- LPTX N/A
- Fundamental
- Price
- CXE $3.69
- LPTX $0.31
- Analyst Decision
- CXE
- LPTX Buy
- Analyst Count
- CXE 0
- LPTX 2
- Target Price
- CXE N/A
- LPTX $8.00
- AVG Volume (30 Days)
- CXE 62.9K
- LPTX 5.8M
- Earning Date
- CXE 01-01-0001
- LPTX 03-26-2025
- Dividend Yield
- CXE 4.36%
- LPTX N/A
- EPS Growth
- CXE N/A
- LPTX N/A
- EPS
- CXE 0.07
- LPTX N/A
- Revenue
- CXE N/A
- LPTX N/A
- Revenue This Year
- CXE N/A
- LPTX N/A
- Revenue Next Year
- CXE N/A
- LPTX N/A
- P/E Ratio
- CXE $51.00
- LPTX N/A
- Revenue Growth
- CXE N/A
- LPTX N/A
- 52 Week Low
- CXE $2.95
- LPTX $0.28
- 52 Week High
- CXE $3.67
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- CXE 41.27
- LPTX 25.59
- Support Level
- CXE $3.66
- LPTX $0.41
- Resistance Level
- CXE $3.75
- LPTX $0.65
- Average True Range (ATR)
- CXE 0.03
- LPTX 0.05
- MACD
- CXE -0.00
- LPTX 0.03
- Stochastic Oscillator
- CXE 26.70
- LPTX 6.78
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .